Bolt Biotherapeutics is an American clinical-stage immuno-oncology company that engages in the discovery, development, and commercialization of pharmaceutical products. It was founded in 2015 and is based Redwood city, California.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Bolt Biotherapeutics news
13.05.2022
Bolt Biotherapeutics' GAAP loss for 3 months of 2022 was $23.678 million, down 3.2% from $24.454 million in the prior year. Revenue amounted to $813 thousand. A year earlier, the company had no revenue.
Source: 
investors.boltbio.com
investors.boltbio.com
31.03.2022
Bolt Biotherapeutics' GAAP loss for 2021 was $98.591 million, up 62.3% from $60.728 million in the previous year. Revenue increased 5.5 times to $1.26 million from $0.231 million a year earlier.
Source: investors.boltbio.com
investors.boltbio.com
09.11.2021
Bolt Biotherapeutics' GAAP loss for 9M 2021 was $71.434 million, up 2.4 times from $29.693 million in the previous year. Revenue increased 3.3-fold to $752,000 from $231,000 a year earlier.
Source: investors.boltbio.com
investors.boltbio.com
13.08.2021
Bolt Biotherapeutics' GAAP loss for 6M 2021 was $48.039 million, up 2.4 times from $19.692 million in the previous year. The company did not receive any revenues in the reporting period. A year earlier the indicator was $0.231 mln.
Source: investors.boltbio.com
investors.boltbio.com
General information
| Company name | Bolt Biotherapeutics |
|---|---|
| Tags | #pharmacy, #biotechnology |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
| Business address | 900 Chesapeake Drive Redwood City, CA 94063 United States |
| Mailing address | 900 Chesapeake Drive Redwood City, CA 94063 United States |
| Website | investors.boltbio.com |
| Information disclosure | www.sec.gov |
English (US) 